


PHARMACEUTICAL 2017

BELLICUM PHARMACEUTICALS INC ** Bellicum Rank 167 of 313







PHARMACEUTICAL 2017

BELLICUM PHARMACEUTICALS INC ** Bellicum Rank 167 of 313



The relative strengths and weaknesses of BELLICUM PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BELLICUM PHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 128% points. The greatest weakness of BELLICUM PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is -209%, being 208% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	105,610
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,113
Liabilities, Non-Current	0
Other Assets	9,923
Other Compr. Net Income	0
Other Expenses	580
Other Liabilities	20,350
Other Net Income	-861
Property and Equipment	16,504
Research and Development	51,263
Revenues	388
Selling, General and Administrative Expense	16,925

Output Variable	Value in 1000 USD
Assets	132,037
Liabilities	35,463
Expenses	68,768
Stockholders Equity	96,574
Net Income	-69,241
Comprehensive Net Income	-69,241
Economic Capital Ratio	-209%